TUESDAY DEADLINE: Talis Biomedical Corporation Investors with Substantial Losses… – Press Release


SAN DIEGO, March 5, 2022 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers of Talis Biomedical Corporation (NASDAQ:TLIS) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Talis Biomedical’s February 12, 2021 initial public offering (“IPO”) have until this upcoming Tuesday, March 8, 2022 to seek appointment as lead plaintiff in Modrak v. Talis Biomedical Corporation, No. 22-cv-00105.  Initiated on January 7, 2022 in the Northern District of California, the Talis Biomedical class action lawsuit charges Talis Biomedical, certain of its top executives and directors, as well as the underwriters of Talis Biomedical’s IPO with violations of the Securities Act of 1933.  A similar lawsuit, Mitcham v. Talis Biomedical Corporation, No. 22-cv-01039, is also pending in the Northern District of California.


http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)” alt=”Robbins Geller, with 200 lawyers in ten offices, represents U.S. and international institutional investors in contingency-based securities and corporate litigation. The firm has obtained many of the largest securities class action recoveries in history, including the largest securities class action judgment. Please visit http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)”>

If you suffered substantial losses and wish to serve as lead plaintiff of the Talis Biomedical class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Talis Biomedical class action lawsuit must be filed with the court no later than this upcoming Tuesday, March 8, 2022.

CASE ALLEGATIONS: Talis Biomedical purportedly develops…